Reported about 3 hours ago
Eli Lilly's stock has taken a hit following investor concerns regarding GLP-1 drugs and broader industry challenges. Experts suggest that the market reaction may be an overreaction, urging a deeper analysis of the company's potential and the overall market dynamics.
Source: YAHOO